BioSpace News Archive

FDA

2022’s Top 5 FDA Drug Approvals are Major Advancements in Cancer, Cardiovascular Disease and Rare Disorders

The FDA’s top five approvals in 2022 represent an eclectic mix of cancer, cardiovascular and rare disease drugs.

December 22, 2022
·
4 min read
·
Editorial Staff
Business

Eli Lilly Expands RNA Editing Collaboration with ProQR Therapeutics

Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration.

December 22, 2022
·
1 min read
·
Alex Keown
Business

BioSpace’s Top Biopharma M&A Candidates for 2023

Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.

December 22, 2022
·
7 min read
·
Heather McKenzie and George Budwell
I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”

I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette.

December 22, 2022
·
2 min read
How a US Recession Could Affect Biopharma

U.S. recession will inevitably make many biopharma companies change course. However, it could cause some biotechs to change for the better.

December 22, 2022
·
5 min read
·
Christie Adams
Drug Development

Lexicon’s AAK1 Inhibitor Disappoints in Phase II Postherpetic Neuralgia Study

Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.

December 22, 2022
·
2 min read
·
Tristan Manalac
Business

Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal

Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.

December 22, 2022
·
2 min read
·
Tristan Manalac
Pharm Country

Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event

Seelos Therapeutics, Inc. today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023.

December 22, 2022
·
4 min read
Pharm Country

HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Harmony Biosciences Holdings, Inc. today announced that President and CEO, John C. Jacobs will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PT/ 7:30 p.m. ET.

December 22, 2022
·
1 min read
Drug Development

Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC).

December 22, 2022
·
7 min read